Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 217

1.

Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation.

Magaldi TG, Almstead LL, Bellone S, Prevatt EG, Santin AD, DiMaio D.

Virology. 2012 Jan 5;422(1):114-24. doi: 10.1016/j.virol.2011.10.012. Epub 2011 Nov 5.

2.

A novel MLL5 isoform that is essential to activate E6 and E7 transcription in HPV16/18-associated cervical cancers.

Yew CW, Lee P, Chan WK, Lim VK, Tay SK, Tan TM, Deng LW.

Cancer Res. 2011 Nov 1;71(21):6696-707. doi: 10.1158/0008-5472.CAN-11-1271. Epub 2011 Sep 9.

3.

Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells.

Sima N, Wang S, Wang W, Kong D, Xu Q, Tian X, Luo A, Zhou J, Xu G, Meng L, Lu Y, Ma D.

Gynecol Oncol. 2007 Aug;106(2):299-304. Epub 2007 Jun 21.

PMID:
17586029
4.

Honeybee venom possesses anticancer and antiviral effects by differential inhibition of HPV E6 and E7 expression on cervical cancer cell line.

Kim YW, Chaturvedi PK, Chun SN, Lee YG, Ahn WS.

Oncol Rep. 2015 Apr;33(4):1675-82. doi: 10.3892/or.2015.3760. Epub 2015 Jan 28.

PMID:
25633640
6.

Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by Human Papillomavirus type 16.

Woodworth CD, Diefendorf LP, Jette DF, Mohammed A, Moses MA, Searleman SA, Stevens DA, Wilton KM, Mondal S.

Virology. 2011 Dec 5;421(1):19-27. doi: 10.1016/j.virol.2011.09.014. Epub 2011 Oct 5.

7.

Inhibition of cervical cancer cell growth in vitro and in vivo by lentiviral-vector mediated shRNA targeting the common promoter of HPV16 E6 and E7 oncogenes.

Zhou J, Li B, Peng C, Wang F, Fu Z, Zhou C, Hong D, Ye F, Lü W, Xie X.

Antiviral Res. 2013 May;98(2):305-13. doi: 10.1016/j.antiviral.2013.03.010. Epub 2013 Mar 21.

PMID:
23523766
8.

High human papillomavirus oncogene mRNA expression and not viral DNA load is associated with poor prognosis in cervical cancer patients.

de Boer MA, Jordanova ES, Kenter GG, Peters AA, Corver WE, Trimbos JB, Fleuren GJ.

Clin Cancer Res. 2007 Jan 1;13(1):132-8.

9.

HPV-16 E6/E7 promotes cell migration and invasion in cervical cancer via regulating cadherin switch in vitro and in vivo.

Hu D, Zhou J, Wang F, Shi H, Li Y, Li B.

Arch Gynecol Obstet. 2015 Dec;292(6):1345-54. doi: 10.1007/s00404-015-3787-x. Epub 2015 Jun 21.

PMID:
26093522
10.

Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed phenotype in HPV16/18-positive cervical cancer cells.

Ding W, Hu Z, Zhu D, Jiang X, Yu L, Wang X, Zhang C, Wang L, Ji T, Li K, He D, Xia X, Liu D, Zhou J, Ma D, Wang H.

Clin Cancer Res. 2014 Dec 15;20(24):6495-503. doi: 10.1158/1078-0432.CCR-14-0250. Epub 2014 Oct 21.

12.
13.

Effect of BPV1 E2-mediated inhibition of E6/E7 expression in HPV16-positive cervical carcinoma cells.

Moon MS, Lee CJ, Um SJ, Park JS, Yang JM, Hwang ES.

Gynecol Oncol. 2001 Feb;80(2):168-75.

PMID:
11161855
15.

Inhibition of cervical carcinoma cell line proliferation by the introduction of a bovine papillomavirus regulatory gene.

Hwang ES, Riese DJ 2nd, Settleman J, Nilson LA, Honig J, Flynn S, DiMaio D.

J Virol. 1993 Jul;67(7):3720-9.

17.

Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease.

Kennedy EM, Kornepati AV, Goldstein M, Bogerd HP, Poling BC, Whisnant AW, Kastan MB, Cullen BR.

J Virol. 2014 Oct;88(20):11965-72. doi: 10.1128/JVI.01879-14. Epub 2014 Aug 6.

18.

HPV-16 E2 physical status and molecular evolution in vivo in cervical carcinomas.

Kahla S, Kochbati L, Chanoufi MB, Maalej M, Oueslati R.

Int J Biol Markers. 2014 Mar 24;29(1):e78-85. doi: 10.5301/jbm.5000051.

PMID:
24170557
19.

Role of the retinoblastoma pathway in senescence triggered by repression of the human papillomavirus E7 protein in cervical carcinoma cells.

Psyrri A, DeFilippis RA, Edwards AP, Yates KE, Manuelidis L, DiMaio D.

Cancer Res. 2004 May 1;64(9):3079-86.

20.

HPV16/18 E5, a promising candidate for cervical cancer vaccines, affects SCPs, cell proliferation and cell cycle, and forms a potential network with E6 and E7.

Liao S, Deng D, Hu X, Wang W, Li L, Li W, Zhou J, Xu G, Meng L, Wang S, Ma D.

Int J Mol Med. 2013 Jan;31(1):120-8. doi: 10.3892/ijmm.2012.1168. Epub 2012 Oct 30.

PMID:
23128250
Items per page

Supplemental Content

Write to the Help Desk